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Abstract
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Purpose—Malignant cancer foci develop acidic extracellular environments. Mild acidic
conditions trigger insertion and folding of the pH (low) insertion peptide (pHLIP™) across a
cellular membrane, enabling targeting of such lesions.
Procedures—We employed optical imaging to follow targeting by fluorescent pHLIP given i.v.
in mice. For visualization, Cy5.5 and Alexa750 were covalently attached to the N terminus of
pHLIP, which stays outside of a cell membrane after transmembrane insertion.
Results—We demonstrate that pHLIP targets: (a) tumors of different origins established by
subcutaneous injection of cancer cells, (b) spontaneous prostate tumors in TRAMP mice and (c)
metastatic lesions in lung. pHLIP accumulation in tumors correlates with tumor aggressiveness.
Within a tumor, it stains extracellular spaces and cellular membranes.
Conclusions—Tissue acidity can be detected by pHLIP peptide insertion and used to diagnose
primary tumors, metastatic lesions, and lipid bodies in necrotic tissues. The ability of pHLIP to
differentially bind metastatic and non-metastatic tumors may provide a new approach for
evaluating cancer prognosis.
Keywords
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Introduction
Cells in malignant cancers exhibit an elevated uptake of glucose that leads to tumor acidosis
from the Pasteur and Warburg effects [1–3]. Glucose uptake and acidosis show a positive
correlation with a tumor’s aggressiveness and metastatic potential [4–7]. Therefore,
extracellular acidity may be a useful biomarker to evaluate the prognosis of tumor
development. The pH (low) insertion peptide (pHLIP) is a water-soluble membrane peptide
that inserts and folds across a cellular membrane lipid bilayer in response to low pH [8–10].
Membrane-associated folding of pHLIP occurs within seconds [11] and is accompanied by a
release of energy [12] that can be used to target acidic tumors in vivo and move cell-
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impermeable cargo-molecules across cellular membranes [10–14]. The extent of tumor
labeling, measured by conjugating pHLIP with fluorescent and positron emission
tomography (PET) imaging agents, is directly related to the level of acidity in tumors of
various types established in mice [10, 13, 15].

Materials and Methods
Peptide Synthesis and Conjugation with Fluorescent Dyes
A pHLIP peptide with a single Cys residue near its N terminus
(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET) was synthesized and purified by
Dr. James I. Elliott at Yale University (New Haven, CT). Cy5.5-maleimide (GE Healthcare)
and Alexa750-maleimide (Invitrogen) were used for the conjugation with pHLIP in DMF.
The conjugated peptides were purified by high-performance liquid chromatography (HPLC).
The concentration of each labeled peptide in buffer was determined by absorption,
ε280=13,940 M−1cm−1 for pHLIP, ε674=250,000 M−1cm−1 for Cy5.5 and ε750=240,000
M−1cm−1 for Alexa750. The purity of the constructs was tested by analytical HPLC and
SELDI-TOF mass spectrometry.
Tumor Models
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HeLa, M4A4 (metastatic), and NM2C5 (non-metastatic) human cancer cells with stable
green fluorescent protein (GFP) expression were purchased from ATCC. Primary tumors
were established by subcutaneous injection of cancer cells (106 cells/flank/0.1 mL) of adult
athymic nude mice from Harlan, Inc. TRAMP mice were obtained from the Jackson
Laboratory at 4–5 weeks old. To establish metastases in lungs, M4A4 cancer cells were
given as multiple tail vein injections, resulting in metastatic lung lesions; alternatively, a
primary tumor was established by subcutaneous injection of M4A4 cancer cells and allowed
to grow until it metastasized to the lungs.
Fluorescence Imaging of Mice and Separated Organs
Fluorescence (near infrared -NIR and GFP) imaging was performed on a Kodak Image
Station In-Vivo FX system. A typical imaging procedure includes tail vein or i.p. injection of
1 mg/kg fluorescent pHLIP and imaging of mice at 4, 24, 48, and 72 h post-injection. The
exposure time of Cy5.5 and Alexa750 imaging was 1 min. Imaging was performed while the
animals were under gas anesthesia with supplemental heat provided to maintain core body
temperature. The contrast index (CI) was calculated according to the equation:
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where Fltumor and Flnorm are the fluorescence mean intensities of tumor and normal contra
lateral region of the same area (muscle), respectively, and Flauto is the auto-fluorescence
from the corresponding region measured from an animal that did not receive an injection of
fluorescent pHLIP.
The contrast-to-noise ratio (CNR) was calculated according to the equation:

where Flb and SDb are the signal intensity and the standard deviation of the background.

Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.

Reshetnyak et al.

Page 3

Fluorescence Microscopy and Histology

NIH-PA Author Manuscript

Some tissue samples were examined immediately after dissection with an inverted epifluorescent microscope (IX71 Olympus). We also performed histological studies of tumors
and organs. Tumors and organs were dissected and then fixed by 4% formalin in phosphate
buffered saline (PBS) solution at pH 7.4 for 24 h at 4°C. Tissues were then rinsed with PBS
and placed in a 30% sucrose PBS solution for at least 24 h at 4°C. Samples were mounted in
optimal cutting temperature compound (Sakura Finetek, Torrance, CA) and frozen in dry ice
or in a special folder in a Cryostat at −80°C. The temperature of mounted frozen samples
was equilibrated with the in-working chamber temperature (−13°C) for 5–10 min. Samples
were frozen only one time to minimize tissue damage. The tissue was sectioned at 10–20 μm
in a Vibratome cryostat, and the tissue slices were placed on microscope slides coated with
poly-lysine, dried in air, washed with deionized water and, in some cases, stained with DAPI
(4′,6-diamidino-2-phenylindole) to observe cell nuclei. Each stained and dried section was
covered with a drop of mounting medium (Permount®) and then a cover slip was placed
over the medium. The slides were examined under the fluorescence microscope. To reduce
out of focus light, a deconvolution microscopy technique was used. Z-sectioning was
applied and optical slices were obtained using the ImagePro Plus deconvolution program.
Biodistribution and Blood clearance
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Biodistribution data were obtained by measuring the mean intensity of each organ collected
at various time points after fluorescent pHLIP injection. NIR and GFP fluorescent images
and photos of tumors and organs were taken immediately after organ collection. Blood was
collected postmortem by cutting the aorta immediately after euthanasia by CO2. Each blood
sample was mixed with an equal volume of storage solution (10 mM Tris–HCl pH 7.5, 10
mM EDTA, 10% SDS).
Measurement of Tumor pH
Measurements of the pH in tumors were performed using a needle pH micro-electrode
(MI-419 with a needle diameter of 0.8 mm) and reference electrode (MI-402;
Microelectrodes, Inc.) [16]. The needle pH micro-electrode is inserted into the central part
of a tumor, and the micro-reference electrode is placed into a nearby subcutaneous region.
The pH is then measured in tumors and in the tumor-free contralateral regions. Ten mice
were used in the study.
Processing of the Data
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Tumor margins were established using the EdgeFinder program according to the algorithm
published in Segala et al. [17]. All statistical analysis of the data was performed using
“Statistica 5.0” package. The P level was computed based on the two-tailed test.
All animal studies were conducted according to an approved animal protocol
(AN04-12-011), in compliance with the principles and procedures outlined in the National
Institutes of Health Guide for the Care and Use of Animals.

Results
Targeting of Tumors by Fluorescent pHLIP Is Enhanced by Co-injection of Glucose
Our goals were to show targeting of spontaneous tumors and metastatic foci and to find
whether the enhanced acidity of more aggressive tumors enhances targeting by fluorescent
pHLIP.
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To follow pHLIP in mice after i.v. or i.p. injections, we used two different fluorescent dyes,
Cy5.5 and Alexa750, covalently attached to the N terminus of pHLIP, which stays outside of
the membrane after transmembrane insertion. We observed a slightly higher contrast index
(tumor/muscle ratio) with Alexa750 (Fig. 1), apparently due to a lower accumulation of this
probe in normal tissue. Possible reasons for the difference between the probes include: (1)
reduced tissue absorption due to the short-wavelength shift in absorption and emission of the
Cy5.5 is in comparison with Alexa750 and (2) differences in the chemical properties of the
dyes (Cy5.5 is more hydrophobic and accumulates in skin more than Alexa750). However,
despite the differences, both dyes conjugated to pHLIP show pH-dependent tumor targeting.
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In the present study, we concentrate our attention to the targeting of small tumors (2–4 mm
in diameter). By using GFP-expressing cancer cells, tumors were readily visualized,
allowing assessment of the co-localization of GFP fluorescence and NIR emission of
fluorescent pHLIP in vivo (Fig. 2). Figure 2a shows a representative set of fluorescence
images and combined photo and GFP images obtained at different time points after tail vein
injection of Cy5.5-pHLIP, Cy5.5-pHLIP with co-injection of glucose, and Cy5.5-K-pHLIP.
Fluorescent pHLIP finds tumors in mice within the first 4 h and remains there for more than
72 h, exhibiting a progressive rise in contrast index from 2 to 5 (Fig. 2d). Previously, we
demonstrated that feeding animals with bicarbonated water, which increases tissue pH [18,
19], correlates with a reduction of tumor targeting by pHLIP [15]. Here, we show a positive
correlation between an increase of tumor targeting by pHLIP and intraperitoneal co-injection
of 200 μl of a 25% solution of glucose (Fig. 2a, d, and Table 1). It has previously been
demonstrated that the intracellular pH in a tissue is unaffected by glucose co-injection,
whereas the average extracellular pH decreases after glucose administration and reaches a
minimum level 0.3 pH units below the initial value [16]. As a consequence, the tumor cell
pH gradient increases an average of 0.25–0.3 pH units. It is interesting that, despite the fact
that co-injection of glucose should enhance tumor acidity for only a couple hours after its
administration, we observe statistically significant changes of the fluorescent pHLIP signal
at 24 h. We conclude that tumor targeting at early time points after fluorescent pHLIP
administration in the presence of glucose is enhanced, while removal of the peptide from
non-cancerous tissue was not affected, giving rise to the values of the contrast index
calculated as the ratio of the signal in tumor to that in non-cancerous tissue (see Methods).
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As a control, we used K-pHLIP, a peptide where the two Asp residues in the putative
transmembrane region are replaced with Lys residues, resulting in a loss of pH-dependent
insertion across membranes (over a pH range from 8 to 3) [13]. The contrast index for the
fluorescent-K-pHLIP is about 1.5 (Fig. 2d), which is similar to the contrast index calculated
for tumors after injection of free dyes with no pHLIP (data not shown; Cy5.5 or Alexa750
dyes were reacted with the SH group of a Cys before injection to animals in order to block
the maleimide linkages on both dyes and so to reduce non-specific reactions with proteins in
vivo).
Biodistribution and Blood Clearance
Since pHLIP peptide interacts with cellular membranes, it is not possible to transfer the
entire fluorescent signal to the supernatant for accurate quantification even after
homogenizing and dissolving organs (further processing of tissue with strong acids disrupts
fluorescent dyes). Therefore, we quantified the fluorescent peptide uptake by tumors and
major organs collected at various time points by measuring the fluorescence from the
surfaces of organs (as shown on Fig. 2c) and calculating mean surface intensities (Fig. 2b).
By analyzing the fluorescence intensity from the sliced pieces of each organ (each organ
was sliced into 4–5 pieces), we concluded that the fluorescence signal is distributed
homogeneously in all organs except kidneys and large tumors. The signal in a kidney is
mostly accumulated in the cortex (see Fig. 3 and [13]). In small tumors with no signs of
Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.
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necrotic tissue, fluorescent pHLIP stains the entire tumor mass (Fig. 4a). However, in large
tumors that developed apoptotic cores, a higher accumulation of fluorescent signal in the
tumor core is observed (Fig. 4b). The maximum fluorescent signal was observed in tumors
and major organs at 4 h post-injection. At 24 h, the fluorescence intensity in tumors dropped
2.3-fold, while, in kidney, liver, and muscle, the drop was 6.0, 3.8, and 3.4 times,
respectively (Fig. 2b, d, e and Table 2). At 48 h post-injection, a further drop of intensity
was observed in organs, with smaller reductions of the signal in tumors. In the control
experiment, mice were illuminated for 20 min and four images were collected during the
illumination. The decrease in fluorescence intensity of pHLIP-Alexa750 was less than 2%,
which indicates that photobleaching effect was insignificant. The CNR at 4, 24, 48, and 72 h
of tumor imaging is 149.0±13.8, 75.6±12.3, 45.1±3.8, 29.5±1.9, respectively. The data
presented in Table 2 and Fig. 2b cannot be used to calculate the amount of the injected dose
of the peptide accumulated in tumor and organs; they clearly demonstrate the more rapid
fluorescence signal reduction in main organs relative to that in tumors, leading to
enhancement of the tumor/muscle ratio (Fig. 2e).
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pHLIP is a moderately hydrophobic membrane-binding peptide. We previously
demonstrated its ability to bind to the membrane of red blood cells (without lysing them)
[15]. We assume that red blood cell binding can explain the prolonged circulation of the
peptide in blood (about 10% is present at 4 h post-injection; Fig. 2f). For therapeutic
applications of pHLIP, it could be considered as an advantage, while for nuclear imaging,
faster blood clearance is desirable. Currently, we are testing truncated versions of the pHLIP
peptide with reduced affinity to a lipid bilayer at neutral pH. New pHLIP variants
demonstrate much faster blood clearance, and they might be better suited for nuclear
imaging (work in progress).
Difference in Targeting of Metastatic and Non-metastatic Tumors by pHLIP
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One of our goals is to evaluate the ability of fluorescent pHLIP to distinguish between
metastatic and non-metastatic tumor phenotypes, since it is thought that more aggressive
metastatic tumor phenotypes have a lower extracellular pH and that acidity promotes
metastasis [7, 18]. Therefore, the extracellular pH of primary tumors may be a useful
prognostic parameter for patients. Metastatic and non-metastatic tumors were established in
mice by subcutaneous injection of two melanoma cell lines, M4A4 and NM2C5,
respectively, both derived from the human melanoma cancer cell line, MDA-MB-435.
M4A4 is highly metastatic in nude mice, while NM2C5 is weakly metastatic. When the
primary tumors reached about 5 mm in diameter, Alexa750-pHLIP was given as single i.v.
injection, and imaging was performed within 3 days (Fig. 5a). A statistically significant
difference in tumor targeting was observed (Table 3 and Fig. 5b) and correlated with the
tumor pH measured by a 0.8-mm diameter micro-electrode probe. The more aggressive
tumors created by injection of metastatic M4A4 cancer cells, with a measured pH value of
6.9±0.2, were stained by fluorescent pHLIP 1.5–1.6 times better (Table 3) than nonaggressive tumors (NM2C5 cancer cells) with pH=7.1±0.2.
Targeting of Spontaneously Developed Tumors
Does pHLIP target spontaneous tumors? The data presented in Figs. 2 and 5, as well as data
published previously [10, 13, 15], demonstrate the ability of pHLIP to target tumors
established in mice by subcutaneous injection of cancer cells. Here, we present the results of
targeting of spontaneous adenocarcinomas, choosing the transgenic adenocarcinoma mouse
prostate (TRAMP) model, which is considered as one of the best for the study of prostate
tumor development, growth, and metastasis [20, 21]. Mice expressing high levels of the
transgene display progressive forms of prostatic disease that histologically resemble human
prostate cancer ranging from mild intra-epithelial hyperplasia to large multinodular
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malignant neoplasia to adenocarcinomas with metastases. Fluorescent pHLIP was
administrated as a single i.p. injection to TRAMP mice that had developed prostate tumors.
The mouse chest was opened the day after injection, and the fluorescent images of the whole
mouse, tumor and major organs were taken (Fig. 6). A high level of fluorescent pHLIP
accumulation in the tumor (10.5 mm in diameter) is evident. The fluorescent image of the
tumor sliced into two pieces demonstrates that pHLIP stains the entire tumor mass,
penetrating to the cells in its interior (Fig. 6c), labeling the extracellular space and cellular
membrane (Fig. 6d).
Staining Metastatic Lesions by Fluorescent pHLIP
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Can pHLIP target metastases? Metastasis is largely what makes cancer a lethal disease.
Methods that allow identification and selective treatment of metastatic lesions could be
useful in reducing mortality. Recent studies show that invasive neoplasms that have
enhanced glucose flux compared with normal tissues give an avenue to distinguish benign
from malignant nodules using fluorodeoxyglucose-positron emission tomography [22, 23].
To find whether pHLIP might similarly be used, we investigated the capability of Alexa750pHLIP to mark metastases in lungs. M4A4 cancer cells expressing GFP were used in the
study to unmistakably visualize metastatic foci. In the first type of experiment, cancer cells
were implanted by subcutaneous injection, and when the tumor grew to 10–15 mm in
diameter, Alexa750-pHLIP was administrated as a single i.v. injection. The mouse was
euthanized after 24 h; the primary tumor was removed, and the rest of the body was checked
for metastatic lesions, which have a characteristic GFP fluorescence. Comparison of wholebody fluorescence GFP and NIR images of mice with open chests revealed selective staining
of lung metastases by fluorescent pHLIP (representative image in Fig. 7a). Lungs were
removed and immediately analyzed under the microscope to identify the relative localization
of GFP and NIR fluorescent signals (Fig. 7b–d). Further analysis of the distribution of
fluorescence was evaluated at higher magnification (×100), clearly showing extracellular
and membrane localization of fluorescent pHLIP (Figs. 7 and 8), as expected from our
biophysical studies showing that pHLIP inserts across a lipid bilayer at low pH to form a
stable transmembrane helix and is not taken up by endocytosis [8–10, 12–14].
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In a second type of metastasis experiment, M4A4 cancer cells expressing GFP were
administrated directly into the blood via tail vein injection. Cancer cells circulating in the
blood accumulate in the lungs and Alexa750-pHLIP injected via tail vein targeted metastatic
sites (Fig. 9a). We observed a 2-mm-sized metastatic rib lesion that was marked by
fluorescent pHLIP with high accuracy (Fig. 9b). The EdgeFinder program we have
developed [17] was applied to calculate tumor margins from GFP and Alexa fluorescent
images (Fig. 9c). Contours of GFP and NIR fluorescence shown in red and light blue,
respectively, coincide with sub-millimeter precision.

Discussion
While no specific gene mutation or chromosomal abnormality is common to all cancers,
nearly all solid tumors have elevated aerobic glycolysis and acidosis, regardless of their
tissue or cellular origin [24]. Altered glucose metabolism in cancer cells stimulates
production and accumulation of acid in the extracellular space of tumors. Proliferation of
cancer cells and the formation of metastases are promoted at low extracellular pH, while, at
the same time, normal cells are susceptible to acid-induced apoptosis, facilitating tumor
invasiveness. Altered glucose metabolism and acidification are thought to play a critical role
in cancer biology [4, 25], and these characteristics of tumor growth and progression might
be useful for the detection of primary tumors and metastatic sites, and for the prognosis of
tumor development if appropriate technology can be found [26]. We suggest that the pHLIP
peptide may represent such a technology for fundamental and applied studies.
Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.
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Our data clearly show that fluorescent pHLIP can target, with high accuracy, primary tumors
of different origins established by subcutaneous injection of cancer cells or developed
spontaneously (TRAMP cancer model). It is especially important to note that fluorescent
pHLIP is capable of targeting small tumors, which is important for early cancer diagnostics.
The fluorescent pHLIP is distributed rather uniformly throughout an entire tumor, unless it
has developed a necrotic core, where its accumulation is usually higher. Since pHLIP is a
membrane-binding peptide, we speculate that it might target the lipid bodies present in
apoptotic/necrotic tissue [27]. However, histological analysis should be performed to test
this suggestion. The tumor targeting can be enhanced by co-injection of glucose, which is
known to selectively enhance acidity in tumors. pHLIP identifies metastatic foci in lungs,
suggesting that metastatic lesions are also acidic. The extent of tumor labeling by pHLIP
directly correlates with tumor aggressiveness, which could provide a useful measure of the
metastatic potential of tumors.

Conclusions
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Fluorescent pHLIP might be used for the study of the microenvironments of tumors and
metastases and their development and progression. Combining fluorescent pHLIP with the
EdgeFinder program [17] might allow a surgeon to locate a tumor and identify its border,
with the aim of an accurate and complete removal of all cancer cells during surgical
intervention. pHLIP conjugated with PET, SPECT, and MR imaging agents is currently
being evaluated using various tumor models in mice with the ultimate goal to transfer them
to clinics for tumor diagnosis and therapeutic outcome monitoring. An enhanced level of
acidity correlates with the development and progression, not only of tumors, but also of
other pathological states [28–30]. Therefore, the pHLIP technology might have a wide range
of applications in basic research and medicine for the imaging, assessment, and therapeutic
targeting of acidic tissue.

Acknowledgments
We are grateful to Erin Jansen for the conjugation of fluorescent dyes with pHLIP peptide and to Dr. James Segala
for analysis of metastatic lesion on ribs using EdgeFinder program, and we would like to acknowledge the financial
support from the NIH CA133890 to OAA, DME, and YRK; NIH GM073857 to DME; and DOD BC061356 and
NIH CA125280 to OAA.

References

NIH-PA Author Manuscript

1. Krebs HA. The Pasteur effect and the relations between respiration and fermentation. Essays
Biochem. 1972; 8:1–34. [PubMed: 4265190]
2. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;
8:519–530. [PubMed: 19872213]
3. Wu R, Racker E. Regulatory mechanisms in carbohydrate metabolism. IV. Pasteur effect and
Crabtree effect in ascites tumor cells. J Biol Chem. 1959; 234:1036–1041. [PubMed: 13654314]
4. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a
multidisciplinary study. Cancer Res. 2006; 66:5216–5223. [PubMed: 16707446]
5. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008;
8:56–61. [PubMed: 18059462]
6. Lessi E, Marino ML, Lozupone F, Fais S, De Milito A. Tumor acidity and malignancy: novel
aspects in the design of anti-tumor therapy. Cancer Therapy. 2008; 6:55–66.
7. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental
metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006; 66:6699–6707.
[PubMed: 16818644]
8. Hunt JF, Rath P, Rothschild KJ, Engelman DM. Spontaneous, pH-dependent membrane insertion of
a transbilayer alpha-helix. Biochemistry. 1997; 36:15177–15192. [PubMed: 9398245]

Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.

Reshetnyak et al.

Page 8

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

9. Reshetnyak YK, Segala M, Andreev OA, Engelman DM. A monomeric membrane peptide that lives
in three worlds: in solution, attached to, and inserted across lipid bilayers. Biophys J. 2007;
93:2363–2372. [PubMed: 17557792]
10. Andreev OA, Engelman DM, Reshetnyak YK. Targeting acidic diseased tissue. New technology
based on use of the pH (low) insertion peptide (pHLIP). Chemistry Today. 2009; 27:10–13.
11. Andreev OA, Karabadzhak AG, Weerakkody D, et al. pH (low) insertion peptide (pHLIP) inserts
across a lipid bilayer as a helix and exits by a different path. Proc Natl Acad Sci USA. 2010;
107:4081–4086. [PubMed: 20160113]
12. Reshetnyak YK, Andreev OA, Segala M, Markin VS, Engelman DM. Energetics of peptide
(pHLIP) binding to and folding across a lipid bilayer membrane. Proc Natl Acad Sci USA. 2008;
105:15340–15345. [PubMed: 18829441]
13. Andreev OA, Dupuy AD, Segala M, et al. Mechanism and uses of a membrane peptide that targets
tumors and other acidic tissues in vivo. Proc Natl Acad Sci USA. 2007; 104:7893–7898. [PubMed:
17483464]
14. Reshetnyak YK, Andreev OA, Lehnert U, Engelman DM. Translocation of molecules into cells by
pH-dependent insertion of a transmembrane helix. Proc Natl Acad Sci USA. 2006; 103:6460–
6465. [PubMed: 16608910]
15. Vavere AL, Biddlecombe GB, Spees WM, et al. A novel technology for the imaging of acidic
prostate tumors by positron emission tomography. Cancer Res. 2009; 69:4510–4516. [PubMed:
19417132]
16. Kozin SV, Shkarin P, Gerweck LE. The cell transmembrane pH gradient in tumors enhances
cytotoxicity of specific weak acid chemo-therapeutics. Cancer Res. 2001; 61:4740–4743.
[PubMed: 11406545]
17. Segala J, Engelman DM, Reshetnyak YK, Andreev OA. Accurate analysis of tumor margins using
a fluorescent pH low insertion peptide (pHLIP). Int J Mol Sci. 2009; 10:3478–3487. [PubMed:
20111691]
18. Robey IF, Baggett BK, Kirkpatrick ND, et al. Bicarbonate increases tumor pH and inhibits
spontaneous metastases. Cancer Res. 2009; 69:2260–2268. [PubMed: 19276390]
19. Wesson DE. Dietary HCO3 reduces distal tubule acidification by increasing cellular HCO3
secretion. Am J Physiol. 1996; 271:F132–F142. [PubMed: 8760254]
20. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl
Acad Sci USA. 1995; 92:3439–3443. [PubMed: 7724580]
21. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol. 1996;
24:502–504. [PubMed: 8864193]
22. Kumar R, Alavi A. Clinical applications of fluorodeoxyglucose–positron emission tomography in
the management of malignant melanoma. Curr Opin Oncol. 2005; 17:154–159. [PubMed:
15725921]
23. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing
solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy
planning, and monitoring response of lung cancer. Radiol Clin North Am. 2005; 43:1–21.
[PubMed: 15693644]
24. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab. 2010; 7:7.
25. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of
cancers. J Nucl Med. 2008; 49:24S–42S. [PubMed: 18523064]
26. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic
and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004; 5:531–540.
[PubMed: 15337482]
27. Zoula S, Herigault G, Ziegler A, et al. Correlation between the occurrence of 1H-MRS lipid signal,
necrosis and lipid droplets during C6 rat glioma development. NMR Biomed. 2003; 16:199–212.
[PubMed: 14558118]
28. Kellum JA, Song M, Li J. Science review: extracellular acidosis and the immune response: clinical
and physiologic implications. Crit Care. 2004; 8:331–336. [PubMed: 15469594]

Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.

Reshetnyak et al.

Page 9

NIH-PA Author Manuscript

29. Xiong ZG, Pignataro G, Li M, Chang SY, Simon RP. Acid-sensing ion channels (ASICs) as
pharmacological targets for neuro-degenerative diseases. Curr Opin Pharmacol. 2008; 8:25–32.
[PubMed: 17945532]
30. Holzer P. Acid-sensitive ion channels and receptors. Handb Exp Pharmacol. 2009; 194:283–332.
[PubMed: 19655111]

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.

Reshetnyak et al.

Page 10

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig. 1.

Alexa750-pHLIP and Cy5.5-pHLIP demonstrate slightly different contrast indices. The
contrast index values calculated at different time points after administration of Cy5.5-pHLIP
and Alexa750-pHLIP via tail vein are presented as mean±SD.
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Fig. 2.

pHLIP targets small tumors and targeting is enhanced by co-injection of glucose. a
Targeting of tumors by fluorescent pHLIP is demonstrated by whole-body fluorescence
imaging. NIR fluorescence (top panel; yellow represents highest intensity) and overlays of
visible light (photo) and GFP (green) fluorescence images (bottom panel) of mice are
shown. Tumors were established by subcutaneous injection of GFP-expressing HeLa cancer
cells in the right flanks, and Cy5.5-pHLIP and non-inserting control peptide Cy5.5-K-pHLIP
were given as single i.v. injections, followed by imaging at 4, 24, 48, and 72 h postinjection. Targeting of tumors by Cy5.5-pHLIP was enhanced by intraperitoneal co-injection
of 200 μl of a 25% glucose solution. Images obtained at different time points are presented

Mol Imaging Biol. Author manuscript; available in PMC 2011 December 1.

Reshetnyak et al.

Page 12

NIH-PA Author Manuscript

with maximum contrast. b Surface mean intensities of tumor and major organs collected at
various time points after administration of Cy5.5-pHLIP are presented (the numbers are
found in Table 2). c NIR fluorescence image of tumor and organs collected at 24 h after tail
vein injection of Cy5.5-pHLIP. d The contrast index calculated at different time points after
administration of Cy5.5-pHLIP, Cy5.5-pHLIP with co-injection of glucose and Cy5.5-KpHLIP are presented as mean±SD (the numbers are found in Table 1). e Tumor/muscle,
tumor/kidney, and tumor/liver ratios at various time points of Cy5.5-pHLIP administration
calculated from the Table 2. f Mean intensity of the NIR fluorescence in blood at different
time points after administration of Alexa750-pHLIP as a single i.v. injection.
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Fig. 3.
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Histological study of distribution of fluorescent pHLIP in kidney. a individual fluorescent
images of kidney slices were obtained using a fluorescent microscope with a ×10 objective
and combined into a large image, which clearly demonstrates a predominant staining of the
kidney cortex, particularly in distal tubules. DAPI stained cell nuclei (c and e). Alexa750
fluorescence is shown at ×10 and ×100 magnification on panels b and d, respectively. DAPI
staining of the same area is presented in panels c and e. Fluorescent images at ×100
magnification were obtained by using focal Z-sectioning and a deconvolution program
(ImageProPlus) to subtract the out-of-focus signal.
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Fig. 4.
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pHLIP staining of tumors. NIR, GFP, and overlay images of small (a; 1.5×3 mm) and large
(b; 8×8 mm) tumors cut in half are shown. In the small tumors, NIR (as well as GFP)
fluorescence distributed homogeneously, while the necrotic cores of large tumors (which has
much less GFP signal) are preferentially stained by fluorescent pHLIP.
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Fig. 5.
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Fluorescent pHLIP can distinguish between metastatic (M4A4) and non-metastatic
(NM2C5) tumors by better targeting of the more aggressive tumor phenotype. a Visible light
(photo), GFP, and NIR (Alexa750-pHLIP) fluorescence images of mice bearing metastatic
(M4A4) and non-metastatic (NM2C5) tumors are presented. NIR fluorescence is given
using an intensity-scaled rainbow presentation. b Targeting of a metastatic (M4A4) tumor
by Alexa750-pHLIP was higher than of a non-metastatic (NM2C5) tumor. Mean
fluorescence was calculated by using the Kodak image software. Data are presented as mean
±SD (the numbers are found in Table 3).
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Fig. 6.
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Prostate tumor targeting by fluorescent pHLIP is demonstrated in TRAMP mice by wholebody fluorescence imaging. a Overlay of visible light (photo) and NIR (Alexa750-pHLIP;
red) fluorescence images of a TRAMP mouse with open chest taken at 24 h after a single
i.p. injection of fluorescent pHLIP. b Overlay of visible light (photo) and NIR (Alexa750pHLIP) fluorescence images are presented of tumor (1) and major organs [kidneys (2), liver
(3), brain (4), intestine (5), muscle (6), stomach (7), testicles (8), spleen (9), lung (10), heart
(11)] collected 24 h post-injection. c A NIR fluorescent image of a prostate tumor (10.5 mm
in diameter) incised into two halves (one half is shown) demonstrates internal staining of the
entire tumor mass by fluorescent pHLIP. d Distribution of fluorescent pHLIP in a
histological section of tumor. An overlay of DAPI and Alexa750 deconvoluted fluorescence
images (×100 objective) is presented. DAPI stains cell nuclei (blue), while Alexa750 stains
membranes and extracellular compartments.
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Fig. 7.

Fluorescent pHLIP targets metastatic nodules in lungs and is distributed in the extracellular
space and cellular membranes of the tumor cells. A primary tumor was established by
subcutaneous injection of M4A4 cancer cells expressing GFP, and the tumor was grown
until it gave lung metastases. Then, the primary tumor was removed, and Alexa750-pHLIP
was given as a single i.v. injection. One day after injection, the animal was euthanized, the
chest was opened, and whole-body imaging was carried out. a Whole-body GFP, NIR
(Alexa750-pHLIP) fluorescence, and visible light (photo) images are shown. b Colocalization of GFP and NIR fluorescence is shown in the excised lungs. c A metastatic
lesion analyzed under the fluorescence microscope at ×10 magnification demonstrates colocalization of GFP and NIR emission. d A detailed analysis of NIR (Alexa750-pHLIP)
fluorescence distribution was carried at ×100 magnification. The NIR fluorescence is
distributed in the extracellular space (asterisk) with staining of the cellular membrane
(indicated by arrows).
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Fig. 8.
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Distribution of fluorescent pHLIP in histological sections of lung metastatic sites at various
magnifications. The red color represents Alexa750 fluorescence (a, e); the green color
represents the GFP fluorescence of the cancer M4A4 cells (b, f); the blue color shows DAPI
in nuclei (c, g), and the last row (d and h) shows overlays of Alexa750 and DAPI
fluorescence images.
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Fig. 9.
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Fluorescent pHLIP targets metastatic lesions in lungs. Metastases were established by i.v.
injection of M4A4 cancer cells that express GFP. Alexa750-pHLIP was given as a single i.v.
injection. One day after injection, the animal was euthanized, the chest was opened, and
whole-body imaging was carried out. a Whole-body GFP and NIR (Alexa750-pHLIP)
fluorescent images are shown. b Targeting of a millimeter-size metastatic lesion in the ribs
by fluorescent pHLIP is evident. The ruler is in millimeters. c The magnified GFP and
Alexa images of the millimeter-size metastatic rib lesion are shown in (b) with tumor
margins calculated by using the EdgeFinder program. Contours of GFP and NIR
fluorescence, shown in red and light blue, respectively, coincide with sub-millimeter
precision.
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1.818±0.261

2.512±0.176

2.783±0.299

3.335±0.848

4

24

48

72

8

6

9

4

N

4.367±1.097

3.600±0.872

3.323±0.627

2.489±0.618

Cy5.5-pHLIP, glucose

3

3

3

7

N

0.1280

0.0657

0.0036

0.0726

P level

1.468±0.412

1.733±0.208

1.420±0.270

1.217±0.165

Cy5.5-K-pHLIP

N is the number of animals in each study. P levels are computed based on a two-sided test, using the mean values of Cy5.5-pHLIP administrated as a single i.v. injection and Cy5.5-pHLIP with 25%
glucose co-injection.

Cy5.5-pHLIP

Time, h

Mean values of the contrast index calculated from the whole-body fluorescence images of mice at various time points (4 to 72 h) after injection of Cy5.5pHLIP, Cy5.5-pHLIP with 25% glucose, and Cy5.5-K-pHLIP into mice bearing GFP-HeLa tumors
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Table 2

Mean values of the fluorescence intensity of organs and tumors measured using the Kodak Imager
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4h

24 h

48 h

72 h

Kidney

10729.8±1190.5

1801.1±213.8

644.4±155.5

400.5±65.0

Tumor

2041.7±377.9

1035.7±337.5

823.8±139.8

404.2±53.2

Liver

2390.1±248.4

626.6±80.2

357.4±50.8

212.2±50.7

Bladder

1443.6±243.0

458.1±107.4

242.1±66.4

137.1±21.6

Stomach

1660.9±186.6

359.8±87.0

207.0±61.6

113.1±24.3

Heart

1297.3±153.6

346.3±50.4

231.4±38.7

110.9±17.8

Lung

1496.5±702.2

413.7±105.1

208.9±26.8

110.6±25.7

Muscle

1038.5±252.9

303.1±61.0

152.7±7.1

91.5±14.5

Intestine

1487.1±85.7

276.6±118.8

125.0±50.5

89.1±13.9

Spleen

607.4±16.0

165.5±52.8

92.5±25.0

31.3±14.0

Brain

282.1±36.1

87.6±28.1

30.8±6.7

15.7±4.1

Organs and tumors were collected at different time points after single i.v. Cy5.5-pHLIP injections (four mice were used to calculate the mean
intensity at each time-point).
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3.896±1.001

5.172±2.215

6.157±2.050

24

48

72

8

12

16

NM4A4

3.799±1.147

3.182±1.063

2.806±1.096

CINM2C5

12

18

18

NNM2C5

0.0039

0.0026

0.0050

p-level

The numbers of animals bearing metastatic (M4A4) and non-metastatic (NM2C5) tumors (N), are presented, with P levels computed based on a two-sided test.

CIM4A4

Time, hr

Mean values of the CI calculated from the whole-body fluorescence images of mice at various time points after Cy5.5-pHLIP administration
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